Article
Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.
Cancer medicine - 1 Aug 2023
Chen Ya, Liu Hongyu, Hu Nana, Wang Yanan, Yang Zhengyu, Zhang Junqiang, Han Baohui
Abstract excerpt
OBJECTIVES: Acquired resistance represents a bottleneck to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung cancer. Our study aimed to explore the efficacy of antiangiogenic-based therapy in osimertinib-resistant NSCLC patients and assess the efficacy of anlotinib in vitro study. METHODS: Our multicenter study retrospectively collected 268 osimertinib-resistant NSCLC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.